$2.03
-0.05 (-2.40%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALLO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 observational · 1 with posted results
Held by 13 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, +8 more) · FINRA short interest 9.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell ProductNCT06925685observationalIncidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs | — | Enrolling by invitation | — | Hematologic Malignancies, Solid Tumors | 50 | Jan 2039 | ≤ 4,548 d | 2025-04-13 |
| Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaNCT04696731Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-316Open-label · Treatment | Phase 1 | Active, not recruiting | Genetic: ALLO-316 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | 120 | Jan 2030 | ≤ 1,261 d | 2026-07-17 |
| Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)NCT04416984Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501AOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: ALLO-501A · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | 160 | Feb 2029 | ≤ 924 d | 2026-03-04 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseNCT07085104Incidence of Dose Limiting toxicities (DLTs) and Other Safety ParametersNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Genetic: ALLO-329 · Drug: Cyclophosphamide, Fludarabine | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 66 | Feb 2028 | ≤ 559 d | 2026-07-31 |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273Event-free survival per independent review committee assessmentRandomized · Open-label · Treatment | Phase 2 | Recruiting | Genetic: cemacabtagene ansegedleucel · Drug: Fludarabine, Cyclophosphamide · Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ | Large B-cell Lymphoma | 250 | Dec 2027 | ≤ 499 d | 2026-07-30 |
| Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)NCT04093596Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715Open-label · Treatment | Phase 1 | Completed | Genetic: ALLO-715 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide, Nirogacestat | Relapsed/Refractory Multiple Myeloma | 73 | 2025-01-27actual | — | 2026-05-13 |
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345results2025-12-31Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review CommitteeRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan: Study Protocol with Statistical Analysis Plan Original ↗ · Study Protocol and Statistical Analysis Plan: Study Protocol with Statistical Analysis Plan Amendment 1 ↗ | Phase 2 | Terminatedsponsor's stated reason: Terminated early for business reasons. | Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide · Genetic: ALLO-501A | Relapsed/Refractory Large B Cell Lymphoma | 2 | 2024-02-20actual | — | 2026-03-02 |
| Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaNCT05000450Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Terminated (Halted Prematurely) | Genetic: ALLO-605 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide | Relapsed/Refractory Multiple Myeloma | 6 | 2023-10-11actual | — | 2024-06-28 |
| Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaNCT03939026Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501Open-label · Treatment | Phase 1 | Completed | Genetic: ALLO-501 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide | Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma | 50 | 2021-10-23actual | — | 2026-03-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19